Meeting
2024 ASCO Annual Meeting
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.
Authors
Sajeve Samuel Thomas
Orlando Health Cancer Institute, Orlando, FL
Sajeve Samuel Thomas , Brian Pico , Brian S. Henick , Rom Leidner , Yazan Samhouri , James Isaacs , Jared Weiss , Michael E. Hurwitz , Jaspreet Singh Grewal , Jason J. Luke , Shrikanta Chattopadhyay , Yun Wang , Marlyane Motta , Jim Murray , Debora Barton , Dawn Pinchasik , Gavin MacBeath , Justin C Moser
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT05973487; NCT05812027
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2542)
DOI
10.1200/JCO.2024.42.16_suppl.2542
Abstract #
2542
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.
First Author: Apostolia Maria Tsimberidou
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.
First Author: Apostolia Maria Tsimberidou
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli
Poster
2024 ASCO Annual Meeting
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
First Author: Toshihiko Doi